Best in Class Drug Discovery solutions Evotec Company Overview

Size: px
Start display at page:

Download "Best in Class Drug Discovery solutions Evotec Company Overview"

Transcription

1 Best in Class Drug Discovery solutions Evotec Company Overview Evotec AG, General Company Overview, 30th Annual J.P. Morgan Healthcare Conference, San Francisco, January 2012

2 Forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-lo oking statements contained herein represent the judgement ofevotecasof the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyondourcontrol,andwhichcouldcauseactualresults to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. PAGE 1

3 Agenda Evotec at a glance Strategic background Discovery alliances & Development partnershipsp Financial strategy & Outlook PAGE 2

4 Leader in high quality drug discovery solutions Evotec at a glance 1) 1 Best-in-class in R&D efficiency Complete, systematic, unbiased and most comprehensive infrastructures to significantly reduce costs and accelerate time to discovery decisions 2 3 Profita able & fast growing Double-digit y-o-y revenue growth, profitable, cash generating, strong portfolio of significant strategic alliances First-in-class in targets and deep-pipeline Matured partnered product pipeline includes Phase III, Phase II and Phase I assets, and first-in-class targets for future drug discovery alliances PAGE 3 1) Founded in 1993, Publicly listed on TecDAX (Germany), approx. 70% free float, >600 employees, Headquarter in Hamburg, Germany

5 Agenda Evotec at a glance Strategic background Discovery alliances & Development partnershipsp Financial strategy & Outlook PAGE 4

6 Outsourcing delivers higher capital efficiency Key factors underpinning Evotec s mission 1 Need for higher R&D capital efficiency Discovery outsourcing relative to other stages of value chain 1) In bn US$ ) Not outsourced Outsourced EVT core competence Other EVT competencies Need for more variable than fixed costs Faster investment or Stop loss decisions i 1.8 Discovery 8% Preclinical Phase I Phase II Phase III 53% 33% 36% 19% % Outsourcing PAGE 5 1) Major players: Wuxi Pharma, Biofocus, AMRI, Syngene, PPD, Evotec, ca. 100 fragmented smaller players 2) WallStreet research 2008; evaluate Pharma; BioWorld

7 Managing the transition for long-term growth Key strategy elements Revenue growth 1 in EUR m Portfolio of alliances 2 Number of partnerships 42.7 >20% y-o-y ~ ~ ~35 Phase III, Phase II, Phase I alliances Strategic long-term discovery alliances Drug discovery alliances (e) (e) 3 Milestones to drive profitability in EUR m 4 Platforms for solutions Number of top scientists significantly improved >600 E.g. Proteomics, new target identification technologies (e) (e) PAGE 6

8 ~75% of revenues linked to milestones and royalties Evotec Business model Performance based upside xy ILLUSTRATIVE z ~40% y x Fix cost Pharma Outcome independent base fee Milestone 1 Milestone 2 Milestone 3 Milestone 4 Cost of successful discovery phase Clinical Milestone 1 Clinical Milestone 2 Clinical Milestone 3 Total cost of successful outsourced product development Royalties single to double digit % Milestones allow for profitable growth and innovation investments PAGE 7

9 Agenda Evotec at a glance Strategic background Discovery alliances & Development partnerships p Financial strategy & Outlook PAGE 8

10 Drug discovery alliances & more Our alliance model in drug discovery and product development Core disease biology alliances know-how Metabolics Pain Regenerative Medicine Best-in-class technology platforms & alliances Immunology & Inflammation Oncology CNS PAGE 9

11 Highest productivity in discovery EVO Discover Best from target to IND Disease biology expertise Key strength 1 Complete value chain, with all value creating steps in house (>100 lead series, es, >50 pre-clinical, ca, and clinical candidates) Target Hit Lead PDC 1) IND 2 Proven target ID platform focusing on disease modifying mecha- nisms, regenerating and protecting key tissues and cell types 3 Industry leader in HTS and other platforms (e.g. FBDD, HCS, compound management, chemoproteomics, phosphoproteomics) 2) 4 High quality medicinal chemistry, supported by leading SGDD 3) and computational chemistry Highly experienced program management 5 Comprehensive compound profiling PAGE 10 1) PDC Preclinical Development Candidate 2) HTS High throughput screening; FBBD Fragment-based Drug Discovery (EVOlution); HCS High Content Screening 3) SGDD Structure based drug design

12 Strong portfolio of top-class partners Selected integrated drug discovery alliances targets provided by partners Partners Focus area Upside for Evotec Oncology, pain, inflammation +++ Huntington disease + Various ++ Description Performance-based, multi-target long-term alliance Long-term alliance, focused on the fight against Huntington disease Long-term alliance, focused on multiple targets 1. CNS 2. Immunology ++ Performance-based, long-term alliance, focused on CNS / Immunology targets Pain ++ Performance-based alliance, focused on pain Various ++ Performance-based, multi-target long-term alliance PAGE 11

13 Even higher upside if targets come from Evotec Selected integrated drug discovery alliances targets provided by EVT Partners Focus area Upside for Evotec Description Metabolics, insulin sensitizer Beta cell regeneration factor Diabetes, obesity and metabolic syndrome Research funding, 7 m upfront, > 230 m milestones, royalties Type 1 and 2 diabetes, targeting beta cell mass, Research funding, 5 m upfront, > 250 m milestones, royalties Pain +++ Response ++ prediction VR1 Antagonist, Performance-based alliance, $ 10 m upfront, >$ 170 m milestones, royalties Performance-based alliance, focused on development of response predicting biomarkers; undisclosed financials PAGE 12

14 Deep clinical pipeline without risk Portfolio of product development partnerships Upside Next Indication Partner Status for Evotec milestone Commercials Diabetes 1) Phase III +++ Final Phase III data Milestones, royalties; potential market approx. 500 m Alzheimer s Phase II Phase IIb initiation Milestones, royalties; Disease potential market approx. 3 5 bn Treatment resistant Open Phase II +++ New partnering Open depression Insomnia 2) Phase II ++ Phase IIb start Milestones, royalties Pain Phase I ++ Phase II start Milestones, royalties Inflammation in Phase I/II +++ animal health 3) Others 4) Open Pre-clinical +++ Phase II start Partnering Milestones, royalties Open PAGE 13 1) DiaPep277 is being developed by Andromeda Biotech Ltd and has been partnered with TEVA Pharmaceuticals Industries Ltd 2) Chinese rights only; Safety and Phase IIb study planned starting ) Animal Health (undisclosed) 4) EVT 501 (H3), P2X3,

15 Novel treatment for type 1 diabetes Example 1: Product development alliance with Andromeda/Teva (Phase III) DiaPep 277 A therapeutic treatment for newly diagnosed type 1 diabetes Type 1 diabetes results from the body s failure to produce insulin, and presently requires life long insulin therapy by subcutaneous injection Today there is no therapy able to slow the destruction of insulin secreting pancreatic beta cells DiaPep 277 is targeted to treat newly diagnosed patients, with residual insulin secreting cells About DiaPep 277 DiaPep 277, is a unique peptide of 24 amino acids, derived from human heat shock protein 60 (HSP 60) The peptide acts by modulating the immune system, thus preventing the destruction of pancreatic cells that secrete insulin in response to elevated blood glucose levels PAGE 14

16 DiaPep 277 is progressing towards market entry Example 1: Product development alliance with Andromeda/Teva Development background All development, regulatory responsibilities and costs have been transferred to Andromeda/Teva 1) Phase I and Phase II studies were successfully conducted d Two Phase III studies have to be conducted for registration Teva has a world wide exclusive license to DiaPep 277 Status DiaPep 277 met primary endpoint of 1 st Phase III trial (Beta cell funct tion) DiaPep 277 demonstrated a significant preservation of C-peptide level ls, a marker for assessing insulin secretion by pancreatic cells Additional clinical, safety and efficacy analysis ongoing 2 nd Phase III with approx. 500 patients was already initiated Expected key milestones for Evotec Next milestone is triggered upon final completion of 1 st Phase III study and continued clinical development (mid 2012) Final data of 2 nd Phase III in 2014/2015(e) First sales projected for 2015(e)/2016 PAGE 15 1) DiaPep 277 was owned by DeveloGen (Evotec Göttingen)

17 Novel treatment of Alzheimer s disease Example 2: Product development alliance with Roche (Phase II) EVT 302 an orally active MAO-B inhibitor to slow down progression of Alzheimer's disease (AD) Alzheimer disease (AD) is the most common form of is diagnosed in people over 65 There is no cure for the disease, which worsens as it predicted to affect 1 in 80 people by dementia, most often AD progresses. AD is RG 1577 EVT 302 is targeted to slow down the sym mptoms of AD. This would be demonstrated in cognitive tests such as ADAS-cog 1). About RG 1577 EVT 302 MAO-B is normally present in brain and is responsiblee for break-down of certain neurotransmitters Activity of MAO-B is linked to production of reactive oxygen species, molecules that can cause neuronal damage Blocking the activity of MAO-B should reduce oxidative stress which is expected to slow progression of AD PAGE 16 1) Alzheimer s disease assessment scale cognitive subsection. Current gold standard in AD clinical trial endpoints

18 RG 1577/EVT302 high unmet medical need Example 2: Product development alliance with Roche Development background All development, regulatory responsibilities and costs have been transferred to Roche Phase I and Phase II trials have been conducted partially with different therapeutic goals Safety profile is established Development profile can potentially target stand alone application or treatments Licensing agree ement No further costs to Evotec Upfront payment of $ 10 m Milestones of $ 820 m Double digit royalties Status and expected key milestones for Evotec Large Phase IIb trial in preparation for start in 2012 Phase IIb completion and Phase III start (end 2013/2014) PAGE 17

19 Significant portfolio of high-value assets Examples of other assets Harvard & Evotec beta cell initiative Systematic, unbiased and comprehensive search for novel beta cell targets Identify physiological mechanisms that control beta cell mass Select most relevant targets irrespective of treatment modality small molecules, biologicals P2X7 receptor (partnered for veterenary use only) ATP-gated ion channel which is thought to play important role in inflammatory processes Animal health: partnered with top-tier tier player; milestones and significant royalties Human applications (unpartnered ) NR2B selective NMDA antagonists for depression indications Potent, selective and orally active / NR2B selective NMDA antagonists (EVT 101/103) Completed multiple dose finding studies Solid safety profile Development partnering process ongoing Response prediction platform & other assets Global, quantitative analysis of the cellular Phosphoproteome Biomarker discovery, drug-mode of action analysis in vivo Identification of new drug targets PAGE 18

20 Upgrading initiatives for future discovery alliances Examples to deliver innovative technologies and even better services CureNephron Systematic, unbiased and comprehensive search for novel targets in nephrology Identify physiological mechanisms and relevant targets irrespective of treatment modality First & Best in class HTScreening Screening for biochemical, functional and/or cellular responses using proprietary technologies Next generation superior detection technology and increased assay sensitivity resulting in higher quality data, less false positives and false negatives CureNeuron Systematic, unbiased and comprehensive search for novel targets in neurology Identify physiological mechanisms and relevant targets irrespective of treatment modality Compound Management High tech compound logistics and data management service for Pharma and NGOs Best in class technology for most efficient data management and compound storage Key customer: NIH (US) PAGE 19

21 Agenda Evotec at a glance Strategic background Discovery alliances & Development partnershipsp Financial strategy & Outlook PAGE 20

22 Positioning for sustainable growth Strategic overview Today Build world-class drug discovery capabilities for integrated projects Establish capital efficiency strategy for sustainable profitability latest in 2012 FOCUS & GROW Build global presence with optimal cost leverage Expand disease expertise & upgrade technology platforms Increase upside potential through longterm performance- based alliances INNOVATE Industrialize offerings Integrated risk sharing alliances One-stop-shop solutions Balance innovation with profitability and cash flow generation for op ptimal shareholder value ACC CELERATE & INDUSTRIALIZE Action Plan 2012 Action Plan 2016 PAGE 21

23 Positive trend of all key metrics reflect strength of underlying business Key metrics in m Strong organic revenue growth Focused R&D investments for first in class innovation Sales Key trends ca. 10 Gross margin % (e) 2012(e) Accelerated operating profitability significantly ifi improved ) (e) 2012(e) R&D expense SG&A ratio Free cash flow CAPEX investments Top class scientists (e) 2012(e) Strong liquidity despite significant investments 1 Technology 4 India 12 DeveloGen 15 Kinaxo 12 Compound Focus 44 Acquisitions from >60 Cash status end 11 PAGE 22 1) Including impairment and restructuring expenses

24 Global reach for global projects approx. 600 scientists Evotec worldwide San Francisco, US ~30 employees Compound Procurement Compound QC and storage Abingdon, UK ~215 employees Medicinal chemistry ADMET Structural biology Hamburg, Germany ~200 employees Screening HTS,NMR in vitro & in vivo biology Munich, Germany ~25 employees Phosphoproteomics Chemical proteomics Göttingen, Germany ~40 employees Metabolics Regenerative Medicine Thane, India ~130 employees Library synthesis & mgmt. Development chemistry Sales representation (Boston, Tokyo) Operations & sales representation PAGE 23

25 The right team to deliver innovation, growth and industrialisation Management & shareholder structure LBBW AM TVM Management Capital ~3.0% ~10% ~0.5% Roland Oetker / ROI ~15 % Number of shares: m Listing: Frankfurt TecDAX, OTCBB 52 week high/low: 3.48 / 1.58 Management Board Werner Lanthaler (CEO) Long time experience in biotech & pharma growth organisations Mario Polywka (COO) 18 years Evotec experience Cord Dohrmann (CSO) Outstanding background in metabolics Colin Bond (CFO) Big industry multi-national background Key scientific Advisors Doug Melton Harvard University / HHMI William Jenkins Ex-Novartis Supervisory Board Flemming Ørnskov Bayer Hubert Birner TVM Capital Mary Tanner Peter J. Solomon Walter Wenninger Ex Bayer Roland Oetker ROI Andreas Pinkwart Dean of Leipzig Graduate School of Management PAGE 24

26 Strong news flow Outlook 2012 to come Key milestones for Grow discovery alliances Build at least two significant new integrated discovery alliances Expand existing long-term alliances Show synergies from recent acquisitions 2 Generate optimal pipeline progress At least one significant ifi strategic t deal for clinical i l or pre-clinical i l asset Deliver significant pre-clinical/clinical milestones Generate more innovation upsides within academic collaborations 3 Manage profitability Double-digit y-o-y revenue growth Improve profitability ove r 2011, without infringing innovation power Invest in high-tech upgrade CAPEX program Maintain strong strategic cash position > 60 m PAGE 25

27 Your contact: Dr Werner Lanthaler Chief Executive Officer +49.(0) (0) Fax

Innovation Efficiency Evotec Company Overview

Innovation Efficiency Evotec Company Overview Innovation Efficiency Evotec Company Overview Evotec AG, 31 st Annual J.P. Morgan Healthcare Conference, January 2013 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

Best in Class Drug Discovery solutions Evotec Company Overview

Best in Class Drug Discovery solutions Evotec Company Overview Best in Class Drug Discovery solutions Evotec Company Overview Evotec AG, Company presentation, September 2012 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

Building innovative drug discovery alliances. Profitable. Growth Go

Building innovative drug discovery alliances. Profitable. Growth Go Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains

More information

EVT Execute & EVT Innovate World-class drug discovery

EVT Execute & EVT Innovate World-class drug discovery EVT Execute & EVT Innovate World-class drug discovery Evotec AG, First Quarter Report 2015, 12 May 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements,

More information

EVT Execute & EVT Innovate Leading drug discovery

EVT Execute & EVT Innovate Leading drug discovery EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

Forward step pby step with Action Plan 2016

Forward step pby step with Action Plan 2016 Forward step pby step with Action Plan 2016 Evotec AG, Full-Year Results 2012, Frankfurt/Main, 26 March 2013 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

Building innovative drug discovery alliances. Addressing causes not. symptoms in diabetes

Building innovative drug discovery alliances. Addressing causes not. symptoms in diabetes Building innovative drug discovery alliances Addressing causes not symptoms in diabetes Evotec AG, Analyst information on CureBeta Alliance with Janssen, Hamburg, 2012 Forward-looking statements Information

More information

Building innovative drug discovery alliances

Building innovative drug discovery alliances Building innovative drug discovery alliances Q1 2012 Invest to Grow! Evotec AG, Q1 2012 Interim Report, 10 th May 2012 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

H1 2013 Innovation. efficiency

H1 2013 Innovation. efficiency H1 2013 Innovation efficiency on track Evotec AG, H1 2013 Interim Report, 08 August 2013 Forward-looking statements Information set forth in this presentation contains forward-looking statements, which

More information

Innovation Efficiency Evotec Company Overview. Evotec AG, Company presentation, Jefferies 2015 Global Healthcare Conference, 04 June 2015, New York

Innovation Efficiency Evotec Company Overview. Evotec AG, Company presentation, Jefferies 2015 Global Healthcare Conference, 04 June 2015, New York Innovation Efficiency Evotec Company Overview Evotec AG, Company presentation, Jefferies 2015 Global Healthcare Conference, 04 June 2015, New York Forward-looking statements Information set forth in this

More information

EVT Execute & EVT Innovate Innovation Efficiency

EVT Execute & EVT Innovate Innovation Efficiency EVT Execute & EVT Innovate Innovation Efficiency Evotec AG, H1 2015 Interim Report, 12 August 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements,

More information

Evotec 2014 Execute on Innovate

Evotec 2014 Execute on Innovate Evotec 2014 Execute on Innovate Evotec AG, Full-Year Results 2014, 24 March 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve

More information

Building innovative drug discovery alliances. Company Presentation. Evotec AG, November 2010

Building innovative drug discovery alliances. Company Presentation. Evotec AG, November 2010 Building innovative drug discovery alliances Company Presentation n Evotec AG, November 2010 Forward-looking statements Information set forth in this presentation contains forward-looking statements, which

More information

Q1 2014 Execute on Innovate

Q1 2014 Execute on Innovate Q1 2014 Execute on Innovate Evotec AG, Q1 2014 Interim Report, 14 May 2014 Forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number

More information

Leading Innovation Efficiency Evotec Company Overview

Leading Innovation Efficiency Evotec Company Overview Leading Innovation Efficiency Evotec Company Overview Evotec AG, Company presentation January 2016 Forward-looking statements Information set forth in this presentation contains forward-looking statements,

More information

H1 2014 Strong Execution for more Innovation

H1 2014 Strong Execution for more Innovation H1 2014 Strong Execution for more Innovation Evotec AG, H1 2014 Interim Report, 12 August 2014 Forward-looking statements Information set forth in this presentation contains forward-looking statements,

More information

I. Management Report of the First Quarter 2012

I. Management Report of the First Quarter 2012 I. Management Report of the First Quarter 2012 DATE OF PUBLICATION: 10 MAY 2012 EVOTEC REPORTS CONTINUED STRONG REVENUE GROWTH; IMPLEMENTATION OF ACTION PLAN 2016 LEADS TO UPFRONT INVESTMENTS IN LONG-TERM

More information

Leading Innovation Efficiency Evotec Company Overview

Leading Innovation Efficiency Evotec Company Overview Leading Innovation Efficiency Evotec Company Overview Evotec AG, Company presentation, July 2016 Forward-looking statements Information set forth in this presentation contains forward-looking statements,

More information

Building innovative drug discovery alliances. Introducing JChem for SharePoint at Evotec

Building innovative drug discovery alliances. Introducing JChem for SharePoint at Evotec Building innovative drug discovery alliances Introducing JChem for SharePoint at Evotec Evotec AG, Introducing JChem for SharePoint at Evotec, 22 nd May 2012 Agenda About Evotec About SharePoint SharePoint

More information

I. Management report for the first quarter of 2014 CONTINUING TO ACCELERATE INNOVATION EFFICIENCY STRATEGY IN NEWLY SEGMENTED BUSINESS FORMATION

I. Management report for the first quarter of 2014 CONTINUING TO ACCELERATE INNOVATION EFFICIENCY STRATEGY IN NEWLY SEGMENTED BUSINESS FORMATION I. Management report for the first quarter of 2014 CONTINUING TO ACCELERATE INNOVATION EFFICIENCY STRATEGY IN NEWLY SEGMENTED BUSINESS FORMATION DATE OF PUBLICATION: 14 MAY 2014 FINANCIAL HIGHLIGHTS Revenues

More information

Forward step by step. Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg (Germany), www.evotec.com

Forward step by step. Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg (Germany), www.evotec.com ANNUAL REPORT 2012 Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg (Germany), www.evotec.com FORWARD thinking means forward acting. What does it take to grow? Evotec s answer is the Action

More information

Science is a matter of connections.

Science is a matter of connections. Non-stop performance: Acceleration potential of EVT Execute services see page 06 Roadmap to the future: EVT Innovate s pipeline and its expansion possibilities see page 10 Linked to efficiency: Facts and

More information

I. Management report for the first quarter of 2015

I. Management report for the first quarter of 2015 I. Management report for the first quarter of 2015 VERY STRONG START TO 2015: 22% GROWTH OF GROUP REVENUES, MAINLY DRIVEN BY EVT EXECUTE; MAJOR MULTI- COMPONENT STRATEGIC ALLIANCE WITH SANOFI CLOSED; FULL-YEAR

More information

clear path to sustainability Action Plan 2012 acceleration of the business model is close to completion see page 03 ccommunication 2011 JAN feb OcT

clear path to sustainability Action Plan 2012 acceleration of the business model is close to completion see page 03 ccommunication 2011 JAN feb OcT clear path to sustainability Action Plan 2012 acceleration of the business model is close to completion see page 03 clear communication in 2011 This is visible through our news flow. The following summary...

More information

Innovation Efficiency Evotec Company Overview

Innovation Efficiency Evotec Company Overview Innovation Efficiency Evotec Company Overview Evotec AG, Company presentation October 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements, which

More information

Evotec. Innovating for the changing market. CureX to overcome slowdown in outsourcing. Major pharma alliances expected in next two years

Evotec. Innovating for the changing market. CureX to overcome slowdown in outsourcing. Major pharma alliances expected in next two years Evotec Innovating for the changing market Corporate outlook Pharma & biotech Evotec has accelerated its CureX strategy to counteract the more uncertain outlook in drug discovery outsourcing and enhance

More information

Evotec AG Annual Report 2008 Tomorrow s Drugs Today. Straight on

Evotec AG Annual Report 2008 Tomorrow s Drugs Today. Straight on Evotec AG Annual 2008 Tomorrow s Drugs Today Straight on Condensed Key Figures Evotec AG (IFRS) 2007 2008 08/07 in % Results 1) : Revenues T 32,885 39,613 20 R&D expenses T 36,938 42,537 15 Operating result

More information

Company Profile // May 2012

Company Profile // May 2012 Company Profile // May 2012 1 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

A career on the science park

A career on the science park A career on the science park Onno van de Stolpe December 2014 Copyright 2014 Galapagos NV 1987 MOGEN Agricultural biotech pioneer Design of transgenic plants with improved traits Close link with Prof Schilperoort

More information

ANNUAL REPORT 2010. growth

ANNUAL REPORT 2010. growth ANNUAL REPORT 2010 growth Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology

More information

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo to Acquire Ambit Biosciences For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please

More information

9. WestLB Deutschland Conference. Frankfurt November 16, 2011

9. WestLB Deutschland Conference. Frankfurt November 16, 2011 9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Evotec. A deal to dream for and key data due soon. Sanofi deal: Cost-free expansion. Revenue growth regaining momentum

Evotec. A deal to dream for and key data due soon. Sanofi deal: Cost-free expansion. Revenue growth regaining momentum Evotec A deal to dream for and key data due soon Sanofi deal, Q115 results Pharma & biotech The exceptional deal with Sanofi for its Toulouse facility at no cost provides Evotec with a platform to accelerate

More information

MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME

MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME FOR IMMEDIATE RELEASE MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME - $185 Million Collaboration to Determine All Human Protein Interactions And Decipher Biochemical Pathways

More information

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011 Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included

More information

Company Update. March 2011

Company Update. March 2011 Company Update March 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various

More information

August 28, 2012. Company Update Commerzbank Sector Conference Week

August 28, 2012. Company Update Commerzbank Sector Conference Week August 28, 2012 Company Update Commerzbank Sector Conference Week Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Leading Innovation Efficiency Evotec Company Overview

Leading Innovation Efficiency Evotec Company Overview Leading Innovation Efficiency Evotec Company Overview Evotec AG, Jefferies 2016 Global Healthcare Conference, 08 June 2016 Forward-looking statements Information set forth in this presentation contains

More information

Commerzbank Sector Conference. Frankfurt August 30, 2011

Commerzbank Sector Conference. Frankfurt August 30, 2011 Commerzbank Sector Conference Frankfurt August 30, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices

novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Juan Jenny Li works as a chemistry professional at Novo Nordisk s research centre in Beijing Diabetes Protein Technologies

More information

Eigenkapitalforum 2013. Company Update November 12, 2013

Eigenkapitalforum 2013. Company Update November 12, 2013 Eigenkapitalforum 2013 Company Update November 12, 2013 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

TERM SHEET EXAMPLE. 1 P age

TERM SHEET EXAMPLE. 1 P age 1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

Eudendron: an Innovative Biotech Start-up

Eudendron: an Innovative Biotech Start-up Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description

More information

PLEASE SEE IMPORTANT DISCLOSURES ON PAGES 26-29 OF THIS REPORT

PLEASE SEE IMPORTANT DISCLOSURES ON PAGES 26-29 OF THIS REPORT Initiation Note September 16, 2014 Evotec AG (EVT.F) Furnished by MERRIMAN CAPITAL Financial Entrepreneur Platform Initiation: Capturing Value as Evotec Adds Pipeline Generation to Drug Discovery Engine.

More information

Evotec OAI AG, Second Quarter Report 2002

Evotec OAI AG, Second Quarter Report 2002 Evotec OAI AG, Second Quarter Report 2002 For further information please contact: Anne Hennecke Investor Relations, Corporate Communications +49.(0)40.560 81-286 +49.(0)40.560 81-333 Fax anne.hennecke@evotecoai.com

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H

J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H PURPOSE JDRF, the world s leading non-profit organization

More information

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

exactly. The need for efficiency in developing effective new therapeutics has never been greater. exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,

More information

UBS Global Life Sciences Conference 2011. New York September 19, 2011

UBS Global Life Sciences Conference 2011. New York September 19, 2011 UBS Global Life Sciences Conference 2011 New York September 19, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:

More information

EVT 302 trial results disappoint, but core biz undervalued at current price. FY15 outlook unchanged. Buying opportunity at current price

EVT 302 trial results disappoint, but core biz undervalued at current price. FY15 outlook unchanged. Buying opportunity at current price A cc or # $TypCap$ 1628 1 0 4 2 Page 1/7 Equity flash Trading update Biotechnology BUY (BUY) Target EUR 3.60 (EUR 4.60) Price (last closing price) : EUR 3.20 Upside : 13% Est. change 2015e 2016e EPS -

More information

JAK1 and beyond. Investor Presentation January 2014. Copyright 2014 Galapagos NV

JAK1 and beyond. Investor Presentation January 2014. Copyright 2014 Galapagos NV JAK1 and beyond Investor Presentation January 2014 Copyright 2014 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for your information.

More information

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity

More information

Brand Quality with Asian Advantages

Brand Quality with Asian Advantages Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com

More information

Medical Billing and the Advantages of a Novelized Pharmaceutical Program

Medical Billing and the Advantages of a Novelized Pharmaceutical Program FOR IMMEDIATE RELEASE Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results Holon, ISRAEL February 9, 2016 Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported

More information

Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015

Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015 Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015 Disclaimer 1. This presentation may contain certain forward-looking

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

Investor Presentation NASDAQ:BLFS

Investor Presentation NASDAQ:BLFS Investor Presentation NASDAQ:BLFS Safe Harbor Statement This presentation contains forward-looking statements, including, but not limited to, statements concerning the company s anticipated business and

More information

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011 Deutsches Eigenkapitalforum Frankfurt November 22, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Phase 2b data from EVT 302: a major trigger in 2Q15. BUY recommendation and PT of EUR 4.60 unchanged

Phase 2b data from EVT 302: a major trigger in 2Q15. BUY recommendation and PT of EUR 4.60 unchanged A cc or # $TypCap$ 1628 1 0 4 2 Page 1/7 Equity flash Trading update Biotechnology BUY (BUY) Target EUR 4.60 (EUR 4.60) Price (last closing price) : EUR 3.88 Upside : 18.0% Est. change 2015e 2016e EPS

More information

Q3 2015 Financial Results and Corporate Update. November 4, 2015

Q3 2015 Financial Results and Corporate Update. November 4, 2015 Q3 2015 Financial Results and Corporate Update November 4, 2015 Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs Agenda Introductions and Forward-Looking

More information

Curriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education

Curriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education Curriculum Vitae Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details Private Address: Date, Place of Birth: Marital Status: Nationality: Languages: Stresemannstraße 9, 93477 Maintal, Germany, Tel. +49

More information

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405

More information

An integrated global healthcare company

An integrated global healthcare company An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment

More information

Galapagos reports largest cash balance ever

Galapagos reports largest cash balance ever Regulated information 3 March 2016, 22.00 CET Galapagos reports largest cash balance ever Key 2015 financials: Cash burn of 122 million, in line with guidance Cash balance on 31 December 2015 of 348 million

More information

Ipsen Jefferies Healthcare Conference

Ipsen Jefferies Healthcare Conference Ipsen Jefferies Healthcare Conference November 2015 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive.

More information

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013 Focus on fleet customers SAF-HOLLAND Annual Financial Statements 213 Detlef Borghardt, CEO Wilfried Trepels, CFO March 13, 214 Agenda 1 Financials 3 2 Appendix 21 2 Executive Summary 1 2 3 Group sales

More information

The Commercialization of Technology Concepts into Medical Products

The Commercialization of Technology Concepts into Medical Products The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community

More information

www.iproteos.com Corporate Presentation November, 2013

www.iproteos.com Corporate Presentation November, 2013 www.iproteos.com Corporate Presentation November, 2013 The company Iproteos is an early-stage drug development company founded in 2011: Spin-Out from Institute for Research in Biomedicine (IRB Barcelona)

More information

Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014

Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Oramed Pharmaceuticals, Inc. Initiating Report Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Key data Sector Rating Biotechnology BUY Target Price $45.00

More information

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge

More information

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:

More information

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/

More information

Building innovative drug discovery alliances. Innovation Efficiency Causes, not symptoms

Building innovative drug discovery alliances. Innovation Efficiency Causes, not symptoms Building innovative drug discovery alliances Innovation Efficiency Causes, not symptoms Evotec AG, R&D Day 2013 in New York City, 22 October 2013 Forward-looking statements Information set forth in this

More information

Flamel Technologies Provides Update on Corporate Progress

Flamel Technologies Provides Update on Corporate Progress Flamel Technologies Provides Update on Corporate Progress Clinical Programs Continue to Move Forward Outlines Full Year 2016 Revenue Guidance Lyon, France January 8, 2016 - Flamel Technologies (NASDAQ:

More information

Acucela Inc. IR Meeting

Acucela Inc. IR Meeting Acucela Inc. IR Meeting Tokyo May 20, 2015 Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening

More information

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;

More information

ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES

ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES Dr. Mohammad Alhadj Ali, MD, PgDip, MSc, PhD (UK) with Prof. David Owens (UK) Outline Type 1 Diabetes Immunology of Type 1 Diabetes Treatment of Type 1 Diabetes

More information

Rodman & Renshaw Annual Global Investment Conference. September 13, 2010

Rodman & Renshaw Annual Global Investment Conference. September 13, 2010 Rodman & Renshaw Annual Global Investment Conference September 13, 2010 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

Annual Report on Form 20-F

Annual Report on Form 20-F Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines

More information

Building innovative drug discovery alliances. Evotec Munich. Quantitative Proteomics to Support the Discovery & Development of Targeted Drugs

Building innovative drug discovery alliances. Evotec Munich. Quantitative Proteomics to Support the Discovery & Development of Targeted Drugs Building innovative drug discovery alliances Evotec Munich Quantitative Proteomics to Support the Discovery & Development of Targeted Drugs Evotec AG, Evotec Munich, June 2013 About Evotec Munich A leader

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics

Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics John D Antonio Practice Leader, Licensing & Competitive Intelligence About Paragon We help increase asset value from

More information

Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro

Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;

More information

De novo design in the cloud from mining big data to clinical candidate

De novo design in the cloud from mining big data to clinical candidate De novo design in the cloud from mining big data to clinical candidate Jérémy Besnard Data Science For Pharma Summit 28 th January 2016 Overview the 3 bullet points Cloud based data platform that can efficiently

More information

Knowledge Synergies The New Paradigm of Innovation. Israel Makov

Knowledge Synergies The New Paradigm of Innovation. Israel Makov Knowledge Synergies The New Paradigm of Innovation Israel Makov New England-Israel Life Sciences Summit - October 26, 2009 Pharma Industry Challenges and Pressures At an All-Time High Historically Low

More information

2012 Global Neuro-psychiatric Devices New Product Innovation Award

2012 Global Neuro-psychiatric Devices New Product Innovation Award 2012 Global Neuro-psychiatric Devices New Product Innovation Award Frost & Sullivan s Global Research Platform Frost & Sullivan has over 50 years of expertise in business with a global research organization

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

FINDING PROTEINS THAT HIT THE MARK PROVEN TRACK-RECORD OF PROTEOMICS EXPERTISE

FINDING PROTEINS THAT HIT THE MARK PROVEN TRACK-RECORD OF PROTEOMICS EXPERTISE FINDING PROTEINS THAT HIT THE MARK PROVEN TRACK-RECORD OF PROTEOMICS EXPERTISE Bioanalytical Services Fit-for-Purpose Assays Biomarker Discovery and Development Proven track-record of proteomics expertise

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

If you were diagnosed with cancer today, what would your chances of survival be?

If you were diagnosed with cancer today, what would your chances of survival be? Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. However

More information

Corporate Overview. Dr Robert Scoffin CEO. http;//www.re-pharm.com/ STAND NUMBER: 27 rob@re-pharm.com

Corporate Overview. Dr Robert Scoffin CEO. http;//www.re-pharm.com/ STAND NUMBER: 27 rob@re-pharm.com Corporate Overview Dr Robert Scoffin CEO http;//www.re-pharm.com/ STAND NUMBER: 27 rob@re-pharm.com Re-Pharm Summary > Focus on commercially valuable early stage assets. > Repositioned compounds > Using

More information

Academic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery

Academic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery Academic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery www.pharmacy.unc.edu/cicbdd Stephen V. Frye, Ph.D. University of North Carolina Chapel Hill Outline Why Academic

More information

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013 Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory

More information